TY - JOUR
T1 - The association of diabetes with risk of prostate cancer defined by clinical and molecular features
AU - Feng, Xiaoshuang
AU - Song, Mingyang
AU - Preston, Mark A.
AU - Ma, Wenjie
AU - Hu, Yang
AU - Pernar, Claire H.
AU - Stopsack, Konrad H.
AU - Ebot, Ericka M.
AU - Fu, Benjamin C.
AU - Zhang, Yiwen
AU - Li, Ni
AU - Dai, Min
AU - Liu, Lydia
AU - Giovannucci, Edward L.
AU - Mucci, Lorelei A.
N1 - Generated from Scopus record by KAUST IRTS on 2023-09-21
PY - 2020/8/18
Y1 - 2020/8/18
N2 - Background: To prospectively examine the association between diabetes and risk of prostate cancer defined by clinical and molecular features. Methods: A total of 49,392 men from the Health Professionals Follow-up Study (HPFS) were followed from 1986 to 2014. Data on self-reported diabetes were collected at baseline and updated biennially. Clinical features of prostate cancer included localised, advanced, lethal, low-grade, intermediate-grade, and high-grade. Molecular features included TMPRSS2: ERG and PTEN subtypes. Cox proportional hazards regression models were used to evaluate the association between diabetes and incidence of subtype-specific prostate cancer. Results: During 28 years of follow-up, we documented 6733 incident prostate cancer cases. Relative to men free from diabetes, men with diabetes had lower risks of total (HR: 0.82, 95% CI: 0.75–0.90), localised (HR: 0.82, 95% CI: 0.74–0.92), low-and intermediate-grade prostate cancer (HR: 0.77, 95% CI: 0.66–0.90; HR: 0.77, 95% CI: 0.65–0.91, respectively). For molecular subtypes, the HRs for ERG-negative and ERG-positive cases were 0.63 (0.42–0.95) and 0.72 (0.46–1.12); and for PTEN-intact and PTEN-loss cases were 0.69 (0.48–0.98) and 0.52 (0.19–1.41), respectively. Conclusion: Besides providing advanced evidence for the inverse association between diabetes and prostate cancer, this study is the first to report associations between diabetes and ERG/PTEN defined prostate cancers.
AB - Background: To prospectively examine the association between diabetes and risk of prostate cancer defined by clinical and molecular features. Methods: A total of 49,392 men from the Health Professionals Follow-up Study (HPFS) were followed from 1986 to 2014. Data on self-reported diabetes were collected at baseline and updated biennially. Clinical features of prostate cancer included localised, advanced, lethal, low-grade, intermediate-grade, and high-grade. Molecular features included TMPRSS2: ERG and PTEN subtypes. Cox proportional hazards regression models were used to evaluate the association between diabetes and incidence of subtype-specific prostate cancer. Results: During 28 years of follow-up, we documented 6733 incident prostate cancer cases. Relative to men free from diabetes, men with diabetes had lower risks of total (HR: 0.82, 95% CI: 0.75–0.90), localised (HR: 0.82, 95% CI: 0.74–0.92), low-and intermediate-grade prostate cancer (HR: 0.77, 95% CI: 0.66–0.90; HR: 0.77, 95% CI: 0.65–0.91, respectively). For molecular subtypes, the HRs for ERG-negative and ERG-positive cases were 0.63 (0.42–0.95) and 0.72 (0.46–1.12); and for PTEN-intact and PTEN-loss cases were 0.69 (0.48–0.98) and 0.52 (0.19–1.41), respectively. Conclusion: Besides providing advanced evidence for the inverse association between diabetes and prostate cancer, this study is the first to report associations between diabetes and ERG/PTEN defined prostate cancers.
UR - https://www.nature.com/articles/s41416-020-0910-y
UR - http://www.scopus.com/inward/record.url?scp=85085492306&partnerID=8YFLogxK
U2 - 10.1038/s41416-020-0910-y
DO - 10.1038/s41416-020-0910-y
M3 - Article
SN - 0007-0920
VL - 123
SP - 657
EP - 665
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 4
ER -
